These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34776013)

  • 21. [Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin].
    Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Apr; 48(4):318-23. PubMed ID: 24969458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
    J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.
    Qiao M; Ren W; Guo H; Huo F; Shang Y; Wang Y; Gao M; Pang Y
    Int J Infect Dis; 2021 May; 106():295-299. PubMed ID: 33864922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
    Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis.
    Willby M; Chopra P; Lemmer D; Klein K; Dalton TL; Engelthaler DM; Cegielski JP; Posey JE;
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
    Chaoui I; Oudghiri A; El Mzibri M
    J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
    Chang KC; Yew WW; Chan RC
    J Antimicrob Chemother; 2010 Aug; 65(8):1551-61. PubMed ID: 20542907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of Sequencing in Predicting Ofloxacin Resistance in
    Wang Z; Xie T; Mu C; Sun R; Wang C; Zhao H; Ju H
    Ann Clin Lab Sci; 2018 Jan; 48(1):69-74. PubMed ID: 29530999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
    Jabeen K; Shakoor S; Malik F; Hasan R
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
    Seifert M; Capparelli E; Catanzaro DG; Rodwell TC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.
    Devasia RA; Blackman A; May C; Eden S; Smith T; Hooper N; Maruri F; Stratton C; Shintani A; Sterling TR
    J Antimicrob Chemother; 2009 Jun; 63(6):1173-8. PubMed ID: 19329799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
    Jain A; Dixit P; Prasad R
    Tuberculosis (Edinb); 2012 Sep; 92(5):404-6. PubMed ID: 22789499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.
    Huang TS; Kunin CM; Shin-Jung Lee S; Chen YS; Tu HZ; Liu YC
    J Antimicrob Chemother; 2005 Dec; 56(6):1058-62. PubMed ID: 16204341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Davies Forsman L; Niward K; Kuhlin J; Zheng X; Zheng R; Ke R; Hong C; Werngren J; Paues J; Simonsson USH; Eliasson E; Hoffner S; Xu B; Alffenaar JW; Schön T; Hu Y; Bruchfeld J
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33154028
    [No Abstract]   [Full Text] [Related]  

  • 37. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance mutations among
    Dixit R; Mohan E; Gupta A; Gupta PS; Patni T; Goyal M; Meena RK
    Int J Mycobacteriol; 2023; 12(3):294-298. PubMed ID: 37721235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.